全文获取类型
收费全文 | 153001篇 |
免费 | 12816篇 |
国内免费 | 4774篇 |
专业分类
耳鼻咽喉 | 1063篇 |
儿科学 | 2858篇 |
妇产科学 | 1489篇 |
基础医学 | 23661篇 |
口腔科学 | 2981篇 |
临床医学 | 15381篇 |
内科学 | 19560篇 |
皮肤病学 | 1517篇 |
神经病学 | 7505篇 |
特种医学 | 3202篇 |
外国民族医学 | 22篇 |
外科学 | 12706篇 |
综合类 | 24242篇 |
现状与发展 | 11篇 |
一般理论 | 25篇 |
预防医学 | 10668篇 |
眼科学 | 4229篇 |
药学 | 17000篇 |
14篇 | |
中国医学 | 8086篇 |
肿瘤学 | 14371篇 |
出版年
2023年 | 1739篇 |
2022年 | 2637篇 |
2021年 | 4996篇 |
2020年 | 4731篇 |
2019年 | 5165篇 |
2018年 | 5054篇 |
2017年 | 4891篇 |
2016年 | 4940篇 |
2015年 | 5005篇 |
2014年 | 7886篇 |
2013年 | 8868篇 |
2012年 | 7422篇 |
2011年 | 8574篇 |
2010年 | 7447篇 |
2009年 | 7348篇 |
2008年 | 7419篇 |
2007年 | 8450篇 |
2006年 | 7776篇 |
2005年 | 7783篇 |
2004年 | 6805篇 |
2003年 | 6043篇 |
2002年 | 4457篇 |
2001年 | 4434篇 |
2000年 | 3605篇 |
1999年 | 3308篇 |
1998年 | 2236篇 |
1997年 | 2007篇 |
1996年 | 2114篇 |
1995年 | 2114篇 |
1994年 | 1851篇 |
1993年 | 1689篇 |
1992年 | 1444篇 |
1991年 | 1262篇 |
1990年 | 1053篇 |
1989年 | 999篇 |
1988年 | 936篇 |
1987年 | 723篇 |
1986年 | 538篇 |
1985年 | 631篇 |
1984年 | 666篇 |
1983年 | 429篇 |
1982年 | 518篇 |
1981年 | 434篇 |
1980年 | 378篇 |
1979年 | 315篇 |
1978年 | 257篇 |
1977年 | 204篇 |
1976年 | 244篇 |
1975年 | 151篇 |
1974年 | 124篇 |
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
61.
62.
目的研究生慧汤对APP/PS1(β-amyloid precursor protein/presenilin 1246E)小鼠海马内β淀粉样前体蛋白(Amyloid precursor protein,APP)代谢产物昼夜表达的影响。方法 将56只雄性APP/PS1双转基因痴呆模型小鼠随机分为4组,分别为:痴呆模型组、褪黑素治疗组(0.78 mg·kg-1·d-1)、生慧汤高剂量组(27.0 g·kg-1·d-1)、生慧汤低剂量组(13.5 g·kg-1·d-1),每组14只;对照组为14只雄性C57BL/6J小鼠,连续给药30天。采用Morris水迷宫检测小鼠学习记忆能力,采用酶联免疫吸附检测(ELISA)检测不同时间段取出的海马组织sAPPα含量。对海马β淀粉样蛋白1-40、β淀粉样蛋白1-42表达进行免疫印迹分析。免疫组化(IHC)检测海马CA1区Aβ1-40蛋白的表达。结果 Morris水迷宫结果表明,与对照组相比,模型组上平台潜伏期明显延长、穿越平台次数明显减少(P<0.01);与模型组相比,生慧汤不同剂量组上平台潜伏期明显缩短(P<0.01、P<0.05),穿越平台次数明显增加(P<0.05)。ELISA结果表明,与对照组相比,模型组的sAPPα总量、各时间段(12:00、24:00)sAPPα含量明显减少(P<0.01);与模型组相比,生慧汤不同剂量组sAPPα总量明显增多(P<0.01、P<0.05),生慧汤高剂量组仅能增加12:00 sAPPα含量(P<0.01),生慧汤低剂量组仅能增加24:00 sAPPα含量(P<0.05)。对照组sAPPα含量具有明显昼夜差异(P<0.01)。模型组sAPPα含量的昼夜差异性消失(P>0.05)。生慧汤高剂量组sAPPα含量具有昼夜差异(P<0.01),生慧汤低剂量组sAPPα含量不具有昼夜差异(P>0.05)。Western blot结果显示,与对照组相比,模型组Aβ1-40、Aβ1-42蛋白表达明显增加(P<0.01);与模型组相比,生慧汤高剂量组Aβ1-40、Aβ1-42蛋白表达减少(P<0.05、P<0.01);生慧汤低剂量组仅能减少Aβ1-40蛋白的表达(P<0.05),对Aβ1-42蛋白表达无影响(P>0.05)。免疫组化结果表明,与对照组相比,模型组Aβ1-40表达明显增加(P<0.01);与模型组相比,生慧汤不同剂量组Aβ1-40表达不同程度减少(P<0.01、P<0.05)。结论 生慧汤能够改善5月龄APP/PS1阿尔茨海默病模型小鼠的学习记忆障碍,其机制可能与恢复海马内APP代谢产物sAPPα的昼夜节律性表达、从而减少Aβ的沉积有关。 相似文献
63.
《Taiwanese journal of obstetrics & gynecology》2022,61(6):1082-1085
ObjectiveWe report a low-grade endometrial stromal sarcoma (ESS) with a novel CDKN1A-JAZF1 fusion gene arising from abdominal wall endometrioma.Case reportA 40-year-old woman presented with a 5.5-cm abdominal wall mass juxtaposed to the postoperative scar of two cesarean sections. Histologically, the tumor exhibited obvious tongue-like protrusions into the surrounding tissue, showed spindle cells with multinodular growth pattern that occasionally rotate around small arteries. Immunohistochemically, the tumor cells were positive for CD10, estrogen receptor (ER), progesterone receptor (PR), negatively stained for smooth muscle actin (SMA), CD117, CyclinD1. In addition, a previously undescribed gene fusion between CDNK1A 5′ end of exon 1(NM_000389.5) and JAZF1 3′ end of exon 5 (NM_175,061,3) was reported in this case.ConclusionThis report of ESS suggesting that rapidly growing abdominal wall masses without menstruation-related should be promptly evaluated and treated aggressively. In addition, we have expanded the molecular landscape of low-grade ESS. 相似文献
64.
65.
Loren Saulsberry PhD Ankur Bhargava MD MPH Sharon Zeng BA Jason B. Gibbons PhD Cody Brannan MS Diane S. Lauderdale PhD Robert D. Gibbons PhD 《Health services research》2023,58(4):873-881
Objective
To derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level.Data Sources and Study Setting
The most recent releases of secondary, publicly available data were collected from national U.S. health agencies as well as state and city public health departments.Study Design
The Social Vulnerability Metric (SVM) was constructed from U.S. zip-code level measures (2018) from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality (2016), COVID-19 vaccination (2021), and emergency department visits for asthma (2018). The SVM was also compared with the existing Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) to determine convergent validity and differential predictive validity.Data Collection/Extraction Methods
The data were collected directly from published files available to the public online from national U.S. health agencies as well as state and city public health departments.Principal Findings
The correlation between SVM scores and national age-adjusted county all-cause mortality was r = 0.68. This correlation demonstrated the SVM's robust validity and outperformed the SVI with an almost four-fold increase in explained variance (46% vs. 12%). The SVM was also highly correlated (r ≥ 0.60) to zip-code level health outcomes for the state of California and city of Chicago.Conclusions
The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions. The SVM provides a single measure of SDoH that better quantifies associations with health outcomes. 相似文献66.
67.
《Saudi Pharmaceutical Journal》2022,30(3):185-194
IntroductionAs the American’s Federal Health Insurance Portability and Accountability Act (HIPAA) stated that patients should be allowed to review their medical records, and as information technology is ever more widely used by healthcare professionals and patients, providing patients with online access to their own medical records through a patient portal is becoming increasingly popular. Previous research has been done regarding the impact on the quality and safety of patients’ care, rather than explicitly on medication safety, when providing those patients with access to their electronic health records (EHRs).AimThis narrative review aims to summarise the results from previous studies on the impact on medication management safety concepts of adult patients accessing information contained in their own EHRs.ResultA total of 24 studies were included in this review. The most two commonly studied measures of safety in medication management were: (a) medication adherence and (b) patient-reported experience. Other measures, such as: discrepancies, medication errors, appropriateness and Adverse Drug Events (ADEs) were the least studied.ConclusionThe results suggest that providing patients with access to their EHRs can improve medication management safety. Patients pointed out improvements to the safety of their medications and perceived stronger medication control. The data from these studies lay the foundation for future research. 相似文献
68.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
69.
《The Annals of thoracic surgery》2023,115(1):88-95
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity. 相似文献
70.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献